Expression of VGLL4 and YAP protein in gastric carcinoma tissues and tumor prognosis

Han, Xin-Ying; Liu, Hong-Zheng; Cai, Chun-Yi; Li, Xiuqing; Ju, Ying-Bo; Li, Yanyan; Zhang, Zhigang

doi:10.23736/s0026-4806.18.05692-6

Cited by 4 publications

(3 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In normal and proliferating normal gastric epithelium, low or moderate levels of YAP1 expression are detected, whereas significantly elevated YAP1 levels are consistently observed in both primary and metastatic GC [23,24]. YAP1 expression is strongly positively correlated with lymphatic metastasis and shortened overall survival time, indicating that YAP may be used as an independent prognostic marker for GC [25][26][27]. Moreover, knockdown of YAP markedly suppresses cell proliferation, colony formation, and metastasis in GC cell lines, both in vitro and in vivo [28][29][30].…”

Section: Discussionmentioning

confidence: 99%

RP11-323N12.5 promotes the malignancy and immunosuppression of human gastric cancer by increasing YAP1 transcription

et al. 2020

View full text Add to dashboard Cite

Background YAP1 is a core protein of the Hippo signaling pathway and is associated with malignancy and immunosuppression. In the present study, we discovered a novel lncRNA, RP11-323N12.5, with tumor promotion and immunosuppression activities through enhancing transcription of YAP1. Methods RP11-323N12.5 was identified using GEPIA. Its expression levels and their relationship with clinical features were investigated using clinical samples. The regulation of YAP1 transcription by RP11-323N12.5 was investigated in both GC and T cells, the tumor and immunosuppression promotion roles of RP11-323N12.5 were explored in vitro and in vivo. Results RP11-323N12.5 was the most up-regulated lncRNA in human GC, based on data from the TCGA database. Its transcription was significantly positively correlated with YAP1 transcription, YAP1 downstream gene expression which contribute to tumor growth and immunosuppression. RP11-323N12.5 promoted YAP1 transcription by binding to c-MYC in the YAP1 promoter region. Meanwhile, transcription of RP11-323N12.5 was also regulated by YAP1/TAZ/TEADs activation in GC cells. RP11-323N12.5 had tumor-and immnosuppression-promoting effects by enhancing YAP1 downstream genes in GC cells. Excessive RP11-323N12.5 was also observed in tumor-infiltrating leukocytes (TILs), which may be exosomederived and also be related to enhanced Treg differentiation as a result YAP1 up-regulation. Moreover, RP11-323N12.5 promoted tumor growth and immunosuppression via YAP1 up-regulation in vivo. Conclusions RP11-323N12.5 was the most up-regulated lncRNA in human GC and it promoted YAP1 transcription by binding to c-MYC within the YAP1 promoter in both GC and T cells. RP11-323N12.5 is an ideal therapeutic target in human GC due to its tumor-promoting and immunosuppression characteristics.

show abstract

Section: Discussionmentioning

confidence: 99%

RP11-323N12.5 promotes the malignancy and immunosuppression of human gastric cancer by increasing YAP1 transcription

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Thus, alteration of YAP1 expression and activity has also been shown to be associated with cancer development 12,13 . In gastric cancer, YAP1 expression contributes to poor patient survival 14 . YAP1 acts as an oncogene or possesses an oncogenic effect in gastric cancer 15 and is able to promote gastric cancer cell survival and migration 16 .…”

Section: Introductionmentioning

confidence: 99%

Up‐regulated acylglycerol kinase (AGK) expression associates with gastric cancer progression through the formation of a novel YAP1‐AGK–positive loop

Huang

Cao

Guo

et al. 2020

J Cellular Molecular Medi

View full text Add to dashboard Cite

show abstract

“…The experimental results of Ge et al [17] showed that TAZ is highly expressed in gastric cancer cells, and knocking out TAZ can reverse cisplatin-resistant gastric cancer cells that have undergone epithelial-mesenchymal transition. The mRNA expression of YAP was upregulated in gastric cancer tissues, and it was positively associated with TNM staging, differentiation, age, depth of invasion and lymph node metastasis [18]. In our study, we performed a bioinformatics analysis to clarify the clinical-pathological and prognostic significances of TAZ and YAP mRNA expression in gastric cancer.…”

mentioning

confidence: 97%

The clinicopathological and prognostic values of TAZ and YAP expression in gastric cancer

Shi¹,

Han²,

Zhang³

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: The transcriptional co-activator with PDZ-binding motif(TAZ) and Yes-associated protein(YAP) are well-known members of the Hippo signaling pathway, which may correlated with organ development regulation and interaction between organ and tumor. At the same time, it is closely related to the occurrence and development of tumors. Methods: The purpose of this study is to explore a potential marker that is specific for gastric cancer. In our study, we designed a bioinformatics analysis of the clinicopathological features of TAZ and YAP mRNA expression in gastric cancer using Kaplan-Meier plotter, Oncomine and TCGA databases. Results: According to Kaplan-Meier plotter, the mRNA expression of TAZ and YAP are negatively related with the overall post-progression and first progression survival rates of gastric cancer patients(p＜0.05), even stratified by clinicopathological features(p＜0.05). As shown in Oncomine, TAZ and YAP mRNA expression is higher in gastric cancers than gastric tissue and gastric mucosa(p＜0.05). In TCGA data, univariate analysis showed that age, TNM staging, lymph node metastasis, distant metastasis was correlated with prognosis in patients with gastric cancer(p＜0.05). COX multivariate analysis showed that age and distant metastasis are risk factors affecting the survival of patients with gastric cancer(p＜0.05). Conclusion: TAZ/YAP may be employed as a good molecular market for patients and might help researchers discover a targeted inhibitor for treating gastric cancer.

show abstract

Expression of VGLL4 and YAP protein in gastric carcinoma tissues and tumor prognosis

Cited by 4 publications

References 18 publications

RP11-323N12.5 promotes the malignancy and immunosuppression of human gastric cancer by increasing YAP1 transcription

RP11-323N12.5 promotes the malignancy and immunosuppression of human gastric cancer by increasing YAP1 transcription

Up‐regulated acylglycerol kinase (AGK) expression associates with gastric cancer progression through the formation of a novel YAP1‐AGK–positive loop

The clinicopathological and prognostic values of TAZ and YAP expression in gastric cancer

Contact Info

Product

Resources

About